{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:41:17Z","timestamp":1792802477590,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.annonc.2020.12.009","type":"journal-article","created":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T03:57:00Z","timestamp":1608868620000},"page":"552-559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Combination treatment of copanlisib and gemcitabine in relapsed\/refractory PTCL (COSMOS): an open-label phase I\/II trial"],"prefix":"10.1016","volume":"32","author":[{"given":"H.-Y.","family":"Yhim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-J.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.S.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.-H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2020.12.009_bib1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project","volume":"9","author":"Anderson","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.12.009_bib2","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.12.009_bib3","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.12.009_bib4","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.12.009_bib5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.12.009_bib6","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.12.009_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2020.12.009_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/bjh.13065","article-title":"Targeting PI3-kinase (PI3K), AKT and mTOR axis in lymphoma","volume":"167","author":"Blachly","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2020.12.009_bib9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bjh.16435","article-title":"Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK\/T-cell lymphoma","volume":"189","author":"Huang","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2020.12.009_bib10","first-page":"2465","article-title":"The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma","volume":"35","author":"Hong","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.annonc.2020.12.009_bib11","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.12.009_bib12","first-page":"342","article-title":"PI3K\/Akt\/mTOR inhibitors in breast cancer","volume":"12","author":"Lee","year":"2015","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.annonc.2020.12.009_bib13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2020.12.009_bib14","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.12.009_bib15","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.tranon.2018.04.011","article-title":"Combination of PI3K\/Akt pathway inhibition and Plk1 depletion can enhance chemosensitivity to gemcitabine in pancreatic carcinoma","volume":"11","author":"Mao","year":"2018","journal-title":"Transl Oncol"},{"key":"10.1016\/j.annonc.2020.12.009_bib16","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.12.009_bib17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/biostatistics\/2.2.203","article-title":"Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials","volume":"2","author":"Lin","year":"2001","journal-title":"Biostatistics"},{"key":"10.1016\/j.annonc.2020.12.009_bib18","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.12.009_bib19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.12.009_bib20","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/bjc.2017.428","article-title":"Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer","volume":"118","author":"Kim","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2020.12.009_bib21","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3109\/10428194.2015.1106538","article-title":"Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies","volume":"57","author":"Teh","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"Pt 3","key":"10.1016\/j.annonc.2020.12.009_bib22","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1042\/bj3330471","article-title":"Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling","volume":"333","author":"Shepherd","year":"1998","journal-title":"Biochem J"},{"key":"10.1016\/j.annonc.2020.12.009_bib23","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2020.12.009_bib24","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A\u00a0targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2020.12.009_bib25","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/ng.2916","article-title":"A\u00a0recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma","volume":"46","author":"Yoo","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.annonc.2020.12.009_bib26","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1158\/1535-7163.MCT-14-0768","article-title":"Loss of tuberous sclerosis complex 2 (TSC2) is frequent in hepatocellular carcinoma and predicts response to mTORC1 inhibitor everolimus","volume":"14","author":"Huynh","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2020.12.009_bib27","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1158\/1078-0432.CCR-13-2345","article-title":"Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy","volume":"20","author":"Voss","year":"2014","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420432156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420432156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:02:43Z","timestamp":1760335363000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420432156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0923753420432156"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2020.12.009","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination treatment of copanlisib and gemcitabine in relapsed\/refractory PTCL (COSMOS): an open-label phase I\/II trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2020.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}